I

Immunai pricing

Immunai bills through bespoke enterprise and strategic research partnerships rather than published subscriptions, so there is no rate card and no unit of charge. The public signals are deal ceilings: up to $85 million for the October 2025 inflammatory bowel disease agreement with AstraZeneca covering rights to an identified target, with a further oncology expansion announced in May 2026.

Immunai full profile Immunai alternatives

Pricing terms

How Immunai pricing works

Pricing model: Quotation. Multi year strategic research partnerships with pharmaceutical sponsors, structured around upfronts, milestones and rights to identified targets rather than software licensing.
Implementation: Not published, and likely to be substantial. Engagements require bespoke scientific scoping, ethics and regulatory coordination across sponsor and clinical sites, and integration with sponsor laboratory information management and clinical data systems that third party analysis describes as partnership specific and potentially requiring additional middleware.
Business associate agreement: Not published. Data arrives through sponsor and research collaboration agreements rather than through business associate relationships with covered entities. The published privacy notice sets out consent scope and the controller and processor split for research data and states that directly collected research data is used to train the platform, but no business associate position or United States health privacy scope statement appears anywhere.

These are eligibility ceilings including milestones rather than sums received, and no upfront payments, milestone triggers or royalty terms are disclosed, so realized value cannot be estimated. Other engagements are announced without figures: Teva in November 2024 for oncology and immunology clinical trials, Boehringer Ingelheim in June 2026 for T cell target discovery, and a non commercial dataset partnership with the Parker Institute for Cancer Immunotherapy in April 2025.

Two structural cost points sit with the partner. The delivery model is sample in rather than software out, meaning specimen collection, viability handling, cryopreservation and shipping to Immunai facilities are the buyer's responsibility and cost. And profiling spend scales with cohort size, since single cell RNA, surface protein and immune receptor sequencing are per sample costs, so year one economics depend on how many patients are profiled rather than on a license.

Compared on price

Immunai pricing against its alternatives

Published prices for Immunai and the products closest to it. Each figure is as the vendor publishes it, in its own currency and billing unit.

All Immunai alternatives →

I
ImmunaiNo published price
P
PostEraNo published price
V
Verge LabsPartnership structured, no list pricing
X
Xaira TherapeuticsNot applicable
C
CellarityNot applicable
M
MolcureNo published price
D
Deep GenomicsNo published price
E
Earendil LabsNo published price
I
IktosNo published price

Questions

Immunai pricing, answered

How much does Immunai cost?

Immunai does not publish a price. Immunai bills through bespoke enterprise and strategic research partnerships rather than published subscriptions, so there is no rate card and no unit of charge.

Does Immunai charge an implementation fee?

Not published, and likely to be substantial. Engagements require bespoke scientific scoping, ethics and regulatory coordination across sponsor and clinical sites, and integration with sponsor laboratory information management and clinical data systems that third party analysis describes as partnership specific and potentially requiring additional middleware.

Does Immunai offer a business associate agreement?

Not published. Data arrives through sponsor and research collaboration agreements rather than through business associate relationships with covered entities. The published privacy notice sets out consent scope and the controller and processor split for research data and states that directly collected research data is used to train the platform, but no business associate position or United States health privacy scope statement appears anywhere.